Gabather AB (publ) (GABA.ST)
SEK 0.4
(-3.61%)
SEK 0.4
(-3.61%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.47 Million SEK | 10.79% |
| 2022 | 8.55 Million SEK | -49.67% |
| 2021 | 16.99 Million SEK | 15.19% |
| 2020 | 14.75 Million SEK | 3.34% |
| 2019 | 14.27 Million SEK | -29.65% |
| 2018 | 20.28 Million SEK | 104.17% |
| 2017 | 9.93 Million SEK | 25.88% |
| 2016 | 7.89 Million SEK | 32.43% |
| 2015 | 5.96 Million SEK | 137.07% |
| 2014 | 2.51 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.18 Million SEK | 7.34% |
| 2024 Q2 | 1.72 Million SEK | -45.92% |
| 2023 Q3 | 2.82 Million SEK | 73.18% |
| 2023 Q2 | 1.63 Million SEK | -20.03% |
| 2023 Q1 | 2.04 Million SEK | -17.06% |
| 2023 Q4 | 2.97 Million SEK | 5.02% |
| 2023 FY | 9.47 Million SEK | 10.84% |
| 2022 Q4 | 2.46 Million SEK | 18.48% |
| 2022 Q1 | 1.95 Million SEK | -65.02% |
| 2022 Q2 | 2.06 Million SEK | 5.69% |
| 2022 Q3 | 2.07 Million SEK | 0.82% |
| 2022 FY | 8.55 Million SEK | -49.67% |
| 2021 Q4 | 5.57 Million SEK | 47.46% |
| 2021 FY | 16.99 Million SEK | 15.19% |
| 2021 Q1 | 3.45 Million SEK | 3.16% |
| 2021 Q2 | 4.18 Million SEK | 21.04% |
| 2021 Q3 | 3.78 Million SEK | -9.63% |
| 2020 Q4 | 3.35 Million SEK | -24.46% |
| 2020 FY | 14.75 Million SEK | 3.34% |
| 2020 Q3 | 4.43 Million SEK | 67.61% |
| 2020 Q1 | 4.32 Million SEK | 18.03% |
| 2020 Q2 | 2.64 Million SEK | -38.75% |
| 2019 Q2 | 4.16 Million SEK | 12.09% |
| 2019 Q4 | 3.66 Million SEK | 33.83% |
| 2019 Q3 | 2.73 Million SEK | -34.32% |
| 2019 FY | 14.27 Million SEK | -29.65% |
| 2019 Q1 | 3.71 Million SEK | -9.06% |
| 2018 Q3 | 5.16 Million SEK | -15.65% |
| 2018 Q4 | 4.08 Million SEK | -20.88% |
| 2018 FY | 20.28 Million SEK | 104.17% |
| 2018 Q1 | 4.71 Million SEK | 45.17% |
| 2018 Q2 | 6.12 Million SEK | 29.85% |
| 2017 Q4 | 3.24 Million SEK | 82.73% |
| 2017 Q2 | 2.58 Million SEK | 10.59% |
| 2017 Q1 | 2.33 Million SEK | 4.22% |
| 2017 FY | 9.93 Million SEK | 25.88% |
| 2017 Q3 | 1.77 Million SEK | -31.12% |
| 2016 Q1 | 1.62 Million SEK | 16.42% |
| 2016 FY | 7.89 Million SEK | 32.43% |
| 2016 Q2 | 2.23 Million SEK | 37.45% |
| 2016 Q4 | 2.23 Million SEK | 25.19% |
| 2016 Q3 | 1.78 Million SEK | -20.14% |
| 2015 Q2 | 2.06 Million SEK | 70.53% |
| 2015 Q3 | 1.28 Million SEK | -37.77% |
| 2015 Q4 | 1.39 Million SEK | 9.14% |
| 2015 FY | 5.96 Million SEK | 137.07% |
| 2015 Q1 | 1.2 Million SEK | 11.65% |
| 2014 Q2 | 9000.00 SEK | 0.0% |
| 2014 Q4 | 1.08 Million SEK | 38.19% |
| 2014 FY | 2.51 Million SEK | 0.0% |
| 2014 Q3 | 783 Thousand SEK | 8600.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | 28.493% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | 75.239% |
| BioGaia AB (publ) | 507.08 Million SEK | 98.132% |
| Enzymatica AB (publ) | 79.92 Million SEK | 88.146% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | 75.216% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | 36.348% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | 65.503% |
| Nanexa AB (publ) | 135.78 Million SEK | 93.023% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | 68.536% |
| ODI Pharma AB | -5.00 SEK | 189480100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 98.563% |
| Probi AB (publ) | 208.93 Million SEK | 95.466% |
| Swedencare AB (publ) | 1.12 Billion SEK | 99.16% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 99.899% |
| Toleranzia AB | 6.97 Million SEK | -35.886% |
| Vivesto AB | 355.71 Million SEK | 97.337% |